Synergistic anti-cancer activity of tyrosine kinase inhibitors and paclitaxel with radiation on anaplastic thyroid cancer in vitro and in vivo

Lee, Y.S.; Chang, Hyun; Kim, S.Y.; Chang, Hang Seok; Park, C.S.

doi:10.1093/annonc/mdy302.001

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there is no established protocol for the use of lenvatinib in patients with ATC. Our data suggest that the addition of lenvatinib to existing anticancer drugs may increase the sensitivity to treatment; this confirms previous non-clinical research which suggested synergistic antineoplastic activity resulting from the combined use of chemotherapy, radiotherapy, and TKI inhibitors ( 23 ). However, the potential for toxicity may also increase when combining several treatment modalities; furthermore, AEs are commonly reported with TKI treatment ( 24 , 25 ).…”

Section: Discussionsupporting

confidence: 90%

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Kim

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Background: Survival rates for anaplastic thyroid cancer (ATC) have not improved in the past four decades; however, preliminary clinical data indicate that lenvatinib may provide efficacy benefits for patients with ATC. This real-world study aimed to define the potential role of lenvatinib in ATC by examining the impact of treatment administered alongside existing therapies. Methods: This was a retrospective, single-center analysis of Korean patients with confirmed ATC who received lenvatinib between October 2015 and February 2018. Eighteen patients were included (mean ± standard deviation age, 64.9 ± 11.1 years; 61.1% female). Six [33.3%] had resectable disease that progressed after a combination of surgery, radiotherapy, and chemotherapy, and 12 [66.7%] had unresectable disease that progressed after radiation treatment and chemotherapy. Study endpoints were overall survival (OS) and change in volume of the largest tumor assessed via imaging. Results: Median OS for the 18 lenvatinib-treated patients was 230 days (range 64–839 days). Survival rates at 6 months and 1 year were 61.1 and 22.2%, respectively. Three patients (16.7%) survived beyond 1 year; 15 patients died, of whom four (26.7%) had local disease and 11 (73.3%) had distant metastasis. Two patients (11.1%) had tumor volume increases of 9–10%. The other 16 patients (88.9%) had tumor volume reductions of 2–69%. Six patients (33.3%) had tumor volume reductions ≥50%. Conclusions: In patients with ATC who had progressed on prior therapy, addition of lenvatinib could improve survival duration and reduce tumor volume. Further studies of lenvatinib in ATC are warranted.

show abstract

Section: Discussionsupporting

confidence: 90%

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Kim

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

Synergistic anti-cancer activity of tyrosine kinase inhibitors and paclitaxel with radiation on anaplastic thyroid cancer in vitro and in vivo

Cited by 1 publication

References 0 publications

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Survival With Lenvatinib for the Treatment of Progressive Anaplastic Thyroid Cancer: A Single-Center, Retrospective Analysis

Contact Info

Product

Resources

About